Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas

Sara Sheikhbahaei; Charles Marcus; Nima Hafezi-Nejad; Mehdi Taghipour; Rathan M Subramaniam

doi:10.1016/j.cpet.2015.03.003

Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas

PET Clin. 2015 Jul;10(3):375-93. doi: 10.1016/j.cpet.2015.03.003. Epub 2015 Apr 16.

Authors

Sara Sheikhbahaei¹, Charles Marcus¹, Nima Hafezi-Nejad¹, Mehdi Taghipour¹, Rathan M Subramaniam²

Affiliations

¹ Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
² Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 401 North Broadway, Baltimore, MD 21231, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA. Electronic address: [email protected].

PMID: 26099673
DOI: 10.1016/j.cpet.2015.03.003

Abstract

Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.

Keywords: Computed tomography; Fluorodeoxyglucose; PET; Patient management; Skeletal sarcoma; Soft tissue sarcoma.

Publication types

Review

MeSH terms

Bone Neoplasms / diagnostic imaging*
Bone Neoplasms / pathology
Bone Neoplasms / therapy
Female
Fluorodeoxyglucose F18
Humans
Male
Multimodal Imaging / methods*
Neoplasm Staging
Positron-Emission Tomography / methods*
Prognosis
Radiopharmaceuticals
Sarcoma / diagnostic imaging*
Sarcoma / pathology
Sarcoma / therapy
Soft Tissue Neoplasms / diagnostic imaging*
Soft Tissue Neoplasms / pathology
Soft Tissue Neoplasms / therapy
Tomography, X-Ray Computed / methods*

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18